Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Tumor-Agnostic 2NET 2Endocrine 2Thoracic 1Lymphoid 1

Conditions

Neoplasms 13Neoplasm Metastasis 3Carcinoma 2Adenocarcinoma 1

Interventions

Paclitaxel 9Carboplatin 9pembrolizumab 7Radiotherapy 7Cisplatin 5Axitinib 4Pemetrexed 3Nivolumab 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2fludarabine 2dacomitinib 2catumaxomab 2Trastuzumab 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Nurses 2Interleukin-2 2Gemcitabine 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vatalanib 1temsirolimus 1sovateltide 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × Sunitinib × Tumor-Agnostic × Clear all
NCT04033991 2023-04-06

Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.

Pfizer

Completed
684 enrolled 20 charts
Tumor-Agnostic

Carcinoma, Neoplasms

NCT00137423 2009-09-30

Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer

Pfizer

Phase 2 Completed
107 enrolled 15 charts
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡